{"entity":{"id":"adra1a","kind":"target","name":"ADRA1A","aka":["adrenoceptor alpha 1A","Alpha-1A adrenergic receptor","ADRA1L1","ADRA1C"],"tldr":"ADRA1A (Alpha-1A adrenergic receptor) is a receptor that reads hormone signals inside the cell nucleus. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours and Prostate cancer.","summary":"Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenger pathway, leading to calcium release from intracellular stores and activation of protein kinase C. ADRA1A binds the catecholamine ligands norepinephrine and epinephrine.\n\nOpen Targets scores its association with cancer at 0.58 (direct and indirect evidence; datatypes literature 0.40, genetic association 0.29, clinical 0.86).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:277","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:277"},{"label":"UniProt P35348","url":"https://www.uniprot.org/uniprotkb/P35348/entry"},{"label":"NCBI Gene 148","url":"https://www.ncbi.nlm.nih.gov/gene/148"},{"label":"Ensembl ENSG00000120907","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000120907"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["neuroendocrine","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.86. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"ADRA1A","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:277","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:277","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P35348","url":"https://www.uniprot.org/uniprotkb/P35348/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000120907","url":"https://platform.opentargets.org/target/ENSG00000120907/associations","note":"association with cancer (MONDO_0004992) 0.58; per-cancer scores at or above 0.5: prostate cancer 0.50, neuroendocrine neoplasm 0.51 (GraphQL API, CC0)"}],"distribution":"few-types","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA ADRA1A: RNA tissue enhanced (adipose tissue 21 nTPM, liver 56 nTPM); high antibody staining in 1 normal tissue. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Neuroendocrine tumours, Prostate cancer); Open Targets associates it with 2 specific cancer types at or above 0.5 (benign prostatic hyperplasia, adrenal gland pheochromocytoma). (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas ADRA1A tissue","url":"https://www.proteinatlas.org/ENSG00000120907-ADRA1A/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000120907 associations","url":"https://platform.opentargets.org/target/ENSG00000120907/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:277","ensembl":"ENSG00000120907","uniprot":"P35348","entrez":"148","firstDescribed":1993,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Hirasawa et al, Biochem. Biophys. Res. Commun, 1993, \"Cloning, functional expression and tissue distribution of human cDNA for the alpha 1C-adrenergic receptor\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/8396931/","biology":"Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenger pathway, leading to calcium release from intracellular stores and activation of protein kinase C. ADRA1A binds the catecholamine ligands norepinephrine and epinephrine. Can also couple to G(14) protein. Nuclear ADRA1A forms heterooligomers with ADRA1B to regulate phenylephrine(PE)-stimulated ERK signalling in cardiac myocytes. At the plasma membrane, ADRA1A interacts with CAVIN4/MURC to regulates ERK activation in cardiomyocytes, contributing to the regulation of cardiac hypertrophy. Location: Nucleus membrane; Cell membrane; Cytoplasm; Membrane, caveola (UniProt). Locus 8p21.2 (HGNC).","whereFound":["Neuroendocrine tumours: Open Targets association 0.51 with neuroendocrine neoplasm (MONDO_0019496)","Prostate cancer: Open Targets association 0.50 with prostate cancer (MONDO_0008315)"],"targetClass":"nuclear-receptor","prevalence":[]},"route":"/targets/adra1a/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}